Ultragenyx Pharmaceutical Inc.RARENASDAQ
Loading
Cash Flow Under PressureContracting
Percentile Rank14
Studio
Year-over-Year Change

Operating cash flow minus capital expenditures

Latest
$-472.00M
↓ 30% vs avg
Percentile
P14
Within normal range
Streak
1 yr
Consecutive declineContracting
Average
$-362.24M
Historical baseline
PeriodValueYoY Change
2025$-472.00M-11.9%
2024$-421.68M+19.2%
2023$-521.57M+1.0%
2022$-526.59M-27.9%
2021$-411.79M-133.8%
2020$-176.13M+52.4%
2019$-370.21M-25.6%
2018$-294.64M-14.8%
2017$-256.64M-49.9%
2016$-171.16M-